278597-30-1

Basic information

• Product Name: [3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methanol
• Synonyms: [3-(2,6-DICHLORO-PHENYL)-5-ISOPROPYL-ISOXAZOL-4-YL]-METHANOL;4-IsoxazoleMethanol, 3-(2,6-dichlorophenyl)-5-(1-Methylethyl)-;[3-(2,6-dichlorophenyl)-5-(1-Methylethyl)-4-isoxazolyl]Methanol;[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methanol
• CAS NO: 278597-30-1
• Molecular Formula: C₁₃H₁₃Cl₂NO₂
• Molecular Weight: 286.15
• Mol File: 278597-30-1.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 408.66 °C at 760 mmHg
• Flash Point: 200.951 °C
• Appearance: /
• Density: 1.309g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.57
• CAS DataBase Reference: [3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methanol(CAS DataBase Reference)
• NIST Chemistry Reference: [3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methanol(278597-30-1)
• EPA Substance Registry System: [3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methanol(278597-30-1)

Safety Data

• Hazardous Substances Data: 278597-30-1(Hazardous Substances Data)

Usage

General Description

The chemical [3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methanol, also known as Diclazuril, is an antiprotozoal agent used in veterinary medicine to treat coccidiosis in poultry and other animals. It belongs to the class of isoxazoles and works by inhibiting the development of the parasite Eimeria, which causes coccidiosis. Diclazuril is effective against a wide range of Eimeria species and is administered orally in the form of a water or feed additive. It is considered safe and well-tolerated in animals, with low toxicity and minimal adverse effects.

InChI:InChI=1/C13H13Cl2NO2/c1-7(2)13-8(6-17)12(16-18-13)11-9(14)4-3-5-10(11)15/h3-5,7,17H,6H2,1-2H3

Upstream product

• 3714-77-0 2,6-dichlorobenzaldoxime 
• 6575-28-6 (1E)-2,6-dichlorobenzaldehyde oxime 
• 774605-35-5 ethyl 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carboxylate 
• 6579-27-7 2,6-Dichloro-N-hydroxybenzenecarboximidoyl chloride 
• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 278597-28-7 methyl 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carboxylate 
• 25185-95-9 2,6-dichlorobenzaldoxime 

Downstream Products

• 278597-32-3 3-(2,6-dichlorophenyl)-4-(3'-chloro-4'-formylphenoxy)-methyl-5-isopropyl-isoxazole 
• 1010107-93-3 6-[3-(2,6-dichlorophenyl)-5-isopropyl-isoxazol-4-ylmethoxy]-2-methyl-3-nitro-pyridine 
• 1020570-56-2 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carbaldehyde 
• 1089660-72-9 (E)-3-(2-chloro-4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)styryl)benzoic acid 
• 933799-50-9 3-(2,6-dichlorophenyl)-4-(3'-carbomethoxy-2-chloro-stilben-4-yl)-oxymethyl-5-isopropyl-isoxazole 
• 700835-82-1 tert-butyl 4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylphenylcarbamate 
• 700835-81-0 4-(chloromethyl)-3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole 
• 898253-47-9 4-(bromomethyl)-3-(2,6-dichlorophenyl)-5-isopropyl-isoxazole 
• 1097778-38-5 6-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-2,3-dihydro-1H-inden-1-one 
• 1097776-69-6 5-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-1H-indole 
• 1097776-78-7 methyl 3-[6-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-1,3-benzothiazol-2-yl]benzoate 
• 1097776-90-3 ethyl 4-[5-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-1-benzothien-2-yl]benzoate 
• 1097777-49-5 ethyl 3-[6-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-1-benzothien-2-yl]benzoate 
• 1097777-56-4 methyl 3-[6-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-2-naphthalenyl]benzoate 

Relevant articles and documents

Optical control of the nuclear bile acid receptor FXR with a photohormone

Herein, we report a photoswitchable modulator for a nuclear hormone receptor that exerts its hormonal effects in a light-dependent fashion. The azobenzene AzoGW enables optical control of the farnesoid X receptor (FXR), a key regulator of hepatic bile aci

HETEROCYCLIC FXR MODULATORS

The present technology is directed to compounds of formula (I), compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.

Structure-guided design and synthesis of isoflavone analogs of GW4064 with potent lipid accumulation inhibitory activities

Our group has previously reported a series of isoflavone derivatives with antidyslipidemic activity. With this background, a series of isoflavone analogs of GW4064 were designed, synthesized and evaluated the lipid-lowering activity of analogs. As a result, most of compounds significantly reduced the lipid accumulation in 3T3-L1 adipocytes and four of them (10a, 11, 15c and 15d) showed stronger inhibitory than GW4064. The most potent compound 15d exhibited promising agonistic activity for FXR in a cell-based luciferase reporter assay. Meanwhile, 15d up-regulated FXR, SHP and BSEP gene expression and down-regulated the mRNA expression of lipogenesis gene SREBP-1c. Besides, an improved safety profile of 15d was also observed in a HepG2 cytotoxicity assay compared with GW4064. The obtained biological results were further confirmed by a molecular docking study showing that 15d fitted well in the binding pocket of FXR and interacted with some key residues simultaneously.